Study on endocrine therapy of scirrous type gastric cancer using Medroxyprogesterone acetate

醋酸甲羟孕酮内分泌治疗硬质型胃癌的研究

• 批准号: 63570647
• 负责人: KOJIMA Osamu
• 金额: $ 1.34万
• 依托单位: Kyoto Prectural University of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1989
• 资助国家: 日本
• 起止时间: 1989 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-63570647/
• 关键词: sex hormone receptor in gastric cancer; endocrine therapy of gastric; ER and PgR in gastric cancer; ER and PgR in gastric cancer and prognosis; Tamoxifen administration to gastric cancer; Medroxy-progesterone acetate administration to gastric cancer

1). Characterization of estrogen receptor in human gastric cancer. Estrogen receptor(ER) in human gastric cancer is characterized. 150,40OXg suppernatant was used as cytozol. In the cytozol, sucrose density gradingts showed 5s and 8s binding peaks for ER. Steroid specificity studies showed that estrogen for estradiol-receptor binding was specific inhibitor.2). Both ER and PgR were located at the nuclei of gastric cancer cells. ER positive rate was 29% and PgR positive rate was 10.3%. ER and PgR positive rate were most likely to be associated with poorly differentiated carcinoma, scirrhous type carcinoma and younger female gastric cancer patients.3). The respectable gastric cancer patients with administration of Tamoxifen showed better prognosis than those without administration of tamoxifen.4). The poorly gastric cancer cells ( KATO III ) were inhibited in vivo by Medroxyprogesterone acetate ( 1x10^<-6>M-1x10^<-7>M ).

1）。人胃癌雌激素受体的特性。雌激素受体（ER）在人胃癌中的特点。用150，400 Xg上清液作为细胞唑。在胞质中，蔗糖密度梯度显示ER的5s和8 s结合峰。甾体特异性研究表明雌激素对雌二醇受体的结合具有特异性。ER和PgR均定位于胃癌细胞核。ER阳性率为29%，PgR阳性率为10.3%。ER、PgR阳性率与低分化癌、硬癌及年轻女性胃癌患者相关性最高。应用他莫昔芬的胃癌患者预后较未应用他莫昔芬的胃癌患者好。醋酸甲羟孕酮（1 × 10 ~ 4 μ M-1 × 10 ~ 4 μ M）在体内可抑制胃癌细胞（KATO Ⅲ）的生长<-6><-7>。